Dynamin Inhibitors Enhance Anti-EGFR Antibody Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Cancer treatment resistance to antibody therapy, particularly in EGFR-positive tumors, due to unimpaired ligand-induced EGFR internalization, limits the effectiveness of anti-EGFR antibody therapies like cetuximab and panitumumab, with current methods failing to adequately address resistance mechanisms.
Innovation Solution
Co-administering a dynamin-dependent endocytosis inhibitor with anti-EGFR antibodies to inhibit receptor-mediated endocytosis, enhancing the immune response by maintaining tumor antigens on the cell surface, thereby increasing antibody binding and immune recognition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-EGFR antibodies are administered to treat EGFR-positive tumors, then antibody binding to tumor antigens is achieved, but treatment effectiveness is reduced due to unimpaired ligand-induced EGFR internalization that removes antigens from the cell surface
Solution Approach 1:
The patent applies preliminary anti-action by pre-treating tumor cells with endocytosis inhibitors (such as dynasore, phenylarsine oxide, or bafilomycin A1) before administering anti-EGFR antibodies. This preliminary inhibition of endocytic pathways prevents the internalization and removal of EGFR antigens from the cell surface, ensuring that sufficient antigen remains available for antibody binding and subsequent immune recognition, thereby resolving the contradiction between antibody binding effectiveness and antigen loss through internalization
Solution Approach 2:
The patent converts the harmful effect of unimpaired EGFR internalization (which removes antigens and reduces antibody efficacy) into a beneficial state by using endocytosis inhibitors to block this pathway. The inhibition of endocytosis, which would normally be considered a disruption of cellular function, becomes beneficial by maintaining surface antigen levels and enhancing antibody-dependent cellular cytotoxicity (ADCC), thus transforming the harmful antigen loss mechanism into a therapeutic advantage
2Reliability
If endocytosis inhibitors are used to maintain tumor antigens on the cell surface, then antibody binding is enhanced, but cellular uptake of receptors is blocked
Solution Approach 1:
The patent applies local quality by selectively targeting the endocytic pathway at specific locations and times - using endocytosis inhibitors specifically during the window period when antibody binding is required, while allowing normal receptor trafficking to occur at other times. This localized application of inhibition ensures that antigen maintenance on the surface is achieved without permanently disrupting cellular homeostasis or causing widespread harmful effects from blocked receptor trafficking
Solution Approach 2:
The patent employs periodic action through intermittent or short-duration administration of endocytosis inhibitors, rather than continuous inhibition. This periodic treatment approach maintains sufficient surface antigen levels for effective antibody binding while allowing the cell to resume normal endocytic function during inhibitor-free periods, thereby balancing the need for enhanced antibody binding with the need to avoid prolonged disruption of cellular receptor trafficking and homeostasis
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly enhances the sensitivity of EGFR-positive tumors to anti-EGFR antibody therapy and stimulates an enhanced antibody-dependent cellular cytotoxicity response, improving clinical outcomes by maintaining tumor antigens on the surface, leading to improved immune recognition and treatment efficacy.
Implementation Method 1
inhibit receptor-mediated endocytosis, enhancing the immune response by maintaining tumor antigens on the cell surface
Data Source
Figure 1A~1B
Figure 2~3
Figure 4A~4C
AI summary
The present invention relates to the use of endocytosis inhibitors, including clathrin-dependent endocytosis inhibitors such as inhibitors of dynamin and antibodies, for enhancing the immune response to cancer, and thereby treating cancers including cancer associated receptor positive cancers.